Novel Peptide Camptothecin Drug-linkers for Potent ADCs-Letter
Mol Cancer Ther
.
2022 Jan;21(1):237.
doi: 10.1158/1535-7163.MCT-21-0212.
Authors
David M Goldenberg
1
,
Robert M Sharkey
2
,
Serengulam V Govindan
3
,
Thomas M Cardillo
3
Affiliations
1
Center for Molecular Medicine and Immunology, Mendham, New Jersey.
2
Center for Molecular Medicine and Immunology, Mendham, New Jersey. robmshark@gmail.com.
3
Immunomedics, Inc., a subsidiary of Gilead Sciences, Inc., Morris Plains, New Jersey.
PMID:
34996865
DOI:
10.1158/1535-7163.MCT-21-0212
No abstract available
Publication types
Letter
Comment
MeSH terms
Antineoplastic Agents*
Camptothecin
Humans
Immunoconjugates*
Peptides
Pharmaceutical Preparations*
Substances
Antineoplastic Agents
Immunoconjugates
Peptides
Pharmaceutical Preparations
Camptothecin